Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Certolizumab pegol - UCB

Drug Profile

Certolizumab pegol - UCB

Alternative Names: AutoClicks-Prefilled-Pen; CDP-870; Certolizumab; Cimzia; CIMZIA AutoClicks Prefilled Pen; Cimzia AutoClicks Prefilled Pen; CZP; PHA-738144; Simziya

Latest Information Update: 05 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator UCB
  • Developer Astellas Pharma; UCB; University of Southampton
  • Class Anti-inflammatories; Antirheumatics; Fab fragments; Monoclonal antibodies; Polyethylene glycols
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Ankylosing spondylitis; Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Spondylitis
  • Phase III Interstitial cystitis; Juvenile rheumatoid arthritis
  • Discontinued Cognition disorders

Most Recent Events

  • 17 Dec 2018 UCB completes the phase III CIMPACT trial for Plaque psoriasis in USA, Bulgaria, Czech Republic, France, Germany, Hungary, the Netherlands, Poland and the UK , NCT02346240)
  • 28 Nov 2018 UCB and Astellas Pharma launch Cimzia® AutoClicks® Prefilled Pen in Japan for Rheumatoid arthritis
  • 24 Oct 2018 UCB Biopharma completes the phase III CIMPASI-1 trial in Plaque psoriasis in USA, Canada, Czech Republic, Germany and Hungary (NCT02326298)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top